Skip to Content
Merck
All Photos(1)

Documents

Y0000578

Paroxetine hydrochloride (anhydrous)

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Paroxetine hydrochloride, (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C19H20FNO3 · HCl
CAS Number:
Molecular Weight:
365.83
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

paroxetine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C19H20FNO3.ClH/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;/h1-6,9,14,17,21H,7-8,10-12H2;1H/t14-,17-;/m0./s1

InChI key

GELRVIPPMNMYGS-RVXRQPKJSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Paroxetine hydrochloride (anhydrous) EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yusuke Murata et al.
Journal of affective disorders, 150(3), 1209-1212 (2013-07-03)
Severe sleepiness and excess sleep duration, "Hypersomnia", induced by paroxetine treatment are generally considered adverse drug reactions, however, our experience indicates that patients with depressive disorder who experience "Hypersomnia" during paroxetine treatment have good clinical response. The aim of this
Jie Liu et al.
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 33(4), 462-465 (2013-07-12)
To explore the efficacy of jieyu granule (JG) combined Paroxetine in treating refractory depression (RD) patients of yin deficiency inner heat syndrome (YDIHS). Seventy RD patients of YDIHS were randomly assigned to the experimental group (JG combined Paroxetine) and the
N E Ordyan et al.
Patologicheskaia fiziologiia i eksperimental'naia terapiia, (4)(4), 64-67 (2014-03-20)
The aim of the present work was an estimation of effects of chronic administration of selective serotonin reuptake inhibitors--fluoxetine (5.0 mg/kg, p.o.) and paroxetine (5.0 mg/kg, p.o.) for 14 days of postnatal period on anxiety-like behavior in the prenatally stressed
Mats B Humble et al.
BMC psychiatry, 13, 344-344 (2013-12-24)
The drug treatments of choice for obsessive-compulsive disorder (OCD) are serotonin reuptake inhibitors (SRIs). However, a correlation between the neuropeptide oxytocin in cerebrospinal fluid and the severity of OCD has previously been shown, and oxytocin and serotonin are interconnected within
A little better than placebo is still better than nothing.
Adrian S Dobs
Nature medicine, 19(8), 962-962 (2013-08-08)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service